📌 Key Takeaways
- A 2026 Cell Reports study by Osaka University’s Associate Professor Kosuke Hashimoto found that CD4 cytotoxic T cells (CD4 CTLs)
reach approximately 18% of T cells in supercentenarians (age 110+),
compared to ~4% in people aged 70–90. - The increase appears to begin after age 100 — not suddenly at 110 —
suggesting a gradual adaptive immune remodeling in extreme longevity. - This is a cross-sectional observational study of n=28.
Causality — whether CD4 CTLs cause longevity or cancer protection —
has not been established. - NERO distinguishes what this study suggests from what it proves,
and flags how this data may be misused in longevity clinic marketing.
For decades, immunosenescence — the gradual decline of immune function with age —
has been treated as an inevitable feature of growing old.
A study published in Cell Reports (Elsevier) in August 2026
by Associate Professor Kosuke Hashimoto and colleagues at Osaka University
challenges that assumption in a specific and striking way.
In people who have lived past 110 years,
a rare subset of immune cells called CD4 cytotoxic T cells (CD4 CTLs)
appears to expand — not contract — with advancing age.
The finding builds on the same team’s 2019 discovery of this cell population in supercentenarians,
and now traces the trajectory of that expansion across three age groups.
Japan has the world’s highest concentration of verified supercentenarians.
Osaka University’s longevity research program has been systematically collecting
biological samples from this population since the mid-2010s,
making it one of the few institutions globally with access to this cohort.
INDEX
What Are CD4 Cytotoxic T Cells —
and Why Are They Unusual?
The immune system’s T cells are broadly divided into two functional categories.
CD4+ T cells (Helper T cells): Typically act as coordinators,
directing other immune cells rather than attacking targets directly.
CD8+ T cells (Cytotoxic T cells): The immune system’s direct killers —
they destroy virus-infected cells and cancer cells on contact.
CD4 Cytotoxic T cells (CD4 CTLs): A rare hybrid population.
They carry the CD4 surface marker of helper cells
but also possess cytotoxic (cell-killing) capability.
Under normal conditions, they represent fewer than 5% of circulating T cells.
They have been observed to expand during viral infections and in some aging contexts,
but their role in extreme longevity was unknown before the 2019 Hashimoto study.
Study Design and Limitations —
Reading n=28 Accurately
Sample size: n=28 across three groups:
— Ages 70–90: 8 participants
— Ages 100–109: 10 participants
— Ages 110+: 10 participants
This is a cross-sectional observational study.
It captures a snapshot across age groups — it does not follow individuals over time.
Supercentenarians are, by definition, survival-selected.
We cannot determine whether high CD4 CTL counts contributed to their longevity,
or whether longevity itself produced the CD4 CTL expansion.
This is a classic survivorship bias problem.
The study does not contain direct evidence that CD4 CTLs prevented cancer in these individuals.
The dominant clone accounted for an average of 33.3% of all CD4 CTLs in this group.
Cross-sectional observational study, n=28.
The upward trend in CD4 CTL proportion appears to begin after age 100, not at 110.
What the Study Shows —
and What It Doesn’t Prove
Nature News headlined its coverage:
“How do people live beyond 110? Abundance of cancer-killing cells might be key.”
That framing is attention-grabbing — and partially accurate.
But it compresses a set of observational findings into a causal claim
the study itself does not make.
NERO separates the two.
• The expansion trend begins after age 100, not abruptly at 110.
• CD4 CTLs showed clonal diversification and expansion,
interpreted as an adaptive response to sustained antigenic stimulation.
• Partial overlap was found between CD4 CTL receptor sequences (CDR3β)
and T cell clones previously identified in tumor tissue —
with lung cancer showing the most overlap.
• CD4 CTLs demonstrated cytokine plasticity,
suggesting functional flexibility beyond simple cytotoxicity.
• That high CD4 CTL counts cause extreme longevity.
• That increasing CD4 CTLs in the general population would extend lifespan.
• That this finding is ready for clinical or therapeutic application.
The authors frame their findings as evidence that the immune system
can continue to adapt — even reorganize — at extreme ages,
rather than simply declining.
This is a description of immune adaptation, not a proof of cancer prevention.
The idea that immune aging isn’t simply decline —
that the immune system may actively reorganize at extreme ages —
is one of the most compelling threads in longevity science right now.
What changed in these immune cells after age 100, and why?
That’s the question the next generation of studies will need to answer.
For now, the honest read is: suggestive, not conclusive.
Longevity clinics will likely cite this study to support immune-activation protocols.
That’s a predictable — and problematic — leap.
A cross-sectional study of 28 people cannot support the claim
that boosting CD4 CTLs will extend your life.
The science is genuinely interesting.
The marketing risk is real.
NERO will keep drawing that line.
Summary
- Published in Cell Reports (Elsevier) on August 19, 2026,
by Associate Professor Kosuke Hashimoto et al., Osaka University.
DOI: 10.1016/j.celrep.2026.117728.
Cross-sectional observational study, n=28 across three age groups. - CD4 CTL proportions: ~4% (ages 70–90) → ~10% (ages 100–109) → ~18% (ages 110+).
The dominant clone represented an average of 33.3% of all CD4 CTLs
in the supercentenarian group.
Clonal diversification was also observed. - Causal relationship between CD4 CTL expansion and cancer prevention
or longevity has not been established.
Overlap with tumor-associated T cell receptor sequences is suggestive,
but prospective studies are needed to test causality. - The study’s core contribution is a new conceptual frame:
immune aging is not uniformly degenerative.
After age 100, the immune system may undergo adaptive remodeling.
This is foundational science — not a clinical protocol.
but also possess the ability to kill target cells directly.
Under normal conditions they represent fewer than 5% of circulating T cells.
The Osaka University team first identified their expansion in supercentenarians in 2019;
the 2026 study confirms and extends that finding across a broader age range.
which is suggestive — but it does not establish that these cells actively prevented cancer.
The study is observational and cross-sectional.
Causality requires prospective longitudinal research.
will extend lifespan or reduce cancer risk.
This study describes a pattern observed in people who have already survived to extreme age —
it does not identify a mechanism that can be therapeutically replicated.
Claims to the contrary in clinical or commercial settings are not supported by this research.
Sources:
1. Hashimoto K, Kojima-Ishiyama M, et al. “CD4 CTLs in supercentenarians: Signs of adaptive expansion in healthy aging.” Cell Reports. August 19, 2026. DOI: 10.1016/j.celrep.2026.117728 — Primary source. Cross-sectional observational study, n=28.
2. Nature News. “How do people live beyond 110? Abundance of cancer-killing cells might be key.” nature.com
3. Hashimoto K et al. “Single-cell transcriptomics reveals expansion of cytotoxic CD4 T cells in supercentenarians.” PNAS. 2019;116:24242–24251. (Foundational 2019 study by the same team.)
